Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.
A long-sought goal during the battle against avian influenza is to develop a new generation of vaccines capable of mass immunizing humans as well as poultry (the major source of avian influenza for human infections) in a timely manner. Although administration of the currently licensed influenza vaccine is effective in eliciting protective immunity against seasonal influenza, this approach is associated with a number of insurmountable problems for preventing an avian influenza pandemic. Many of the hurdles may be eliminated by developing new avian influenza vaccines that do not require the propagation of an influenza virus during vaccine production. Replication-competent adenovirus-free adenovirus vectors hold promise as a carrier for influenza virus-free avian influenza vaccines owing to their safety profile and rapid manufacture using cultured suspension cells in a serum-free medium. Simple and efficient mass-immunization protocols, including nasal spray for people and automated in ovo vaccination for poultry, convey another advantage for this class of vaccines. In contrast to parenteral injection of adenovirus vector, the potency of adenovirus-vectored nasal vaccine is not appreciably interfered by pre-existing immunity to adenovirus.
Tang
De-chu C
DC
Vaxin Inc., 1500 First Avenue North, Birmingham, AL 35203, USA. tang@vaxin.com
Zhang
Jianfeng
J
Toro
Haroldo
H
Shi
Zhongkai
Z
Van Kampen
Kent R
KR
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D004196:Disease Outbreaks / Q000517:prevention & control; D005822:Genetic Vectors; D006801:Humans; D009980:Influenza A virus / Q000235:genetics* / Q000276:immunology; D007252:Influenza Vaccines / Q000235:genetics* / Q000276:immunology*; D005585:Influenza in Birds / Q000517:prevention & control; D007251:Influenza, Human / Q000517:prevention & control; D011200:Poultry
D007252:Influenza Vaccines